Arteriovenous fistula (AVF) failure can occur in patients undergoing hemodialysis (HD). In this study, we explored the correlation between hyperlipidemia and AVF failure in patients undergoing HD. Moreover, we compared the lipid profiles of patients with chronic kidney disease (CKD) with those of healthy people to provide a basis for lipid-lowering in patients undergoing HD.
Method and analysis:
We searched PubMed, Web of Science, Embase, the Cochrane library, CNKI, CBM, the China Science Periodical Database, and the China Science and Technology Journal Database. The final search was conducted on August 31, 2021, and the search period was restricted between 2000 and August 31, 2021, without publication restrictions. All studies met the inclusion criteria, and the influences of sex, age, geographical location, diagnosis method, and publication year were excluded. The data were analyzed using the random-effects model and the fixed-effects model.
Results:
Twenty-eight studies were included in the meta-analysis with 121,666 patients in the CKD group and 1714 patients in the AVF failure group. Triglyceride concentration in patients with CKD was higher than in healthy subjects (MD: −31.56, 95% CI: −41.23 to −21.90, p < 0.00001). A high total cholesterol (TC) concentration (MD: 6.97, 95% CI: 2.19–11.74, p = 0.004) and a high low-density lipoprotein cholesterol (LDL-C) concentration (MD: 23.83, 95% CI: 18.48–29.18, p < 0.00001) were associated with AVF failure. Furthermore, HDL-C was lower in the AVF failure group than in the AVF patency group (MD: −2.68, 95% CI: −4.60 to −0.76, p = 0.006).
Conclusion:
Our analysis indicates that the AVF failure may be related to the increase of TC/LDL-C and the decrease of HDL-C. Although current guidelines do not consider intensive lipid-lowering therapy as necessary in patients undergoing HD, our research indicates that patients with AVF undergoing HD may need regular TC/LDL-C-lowering therapy to prevent AVF failure. However, this issue still needs well designed prospective trials.
ShlipakMGTummalapalliSLBoulwareLE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int2021; 99: 34–47.
2.
SaranRRobinsonBAbbottKC, et al. US Renal Data System 2017 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis2018; 71: A7.
3.
CarreroJJHeckingMChesnayeNC, et al. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol2018; 14: 151–164.
4.
WannerCTonelliM. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int2014; 85: 1303–1309.
5.
CozzolinoMManganoMStucchiA, et al. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant2018; 33: iii28–iii34.
6.
LeeSOhHJLeeEK, et al. Blood pressure control during chronic kidney disease progression. Am J Hypertens2017; 30: 610–616.
7.
AttmanPOSamuelssonOAlaupovicP. The effect of decreasing renal function on lipoprotein profiles. Nephrol Dialy Transplant2011; 26: 2572–2575.
8.
FerroCJMarkPBKanbayM, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol2018; 14: 727–749.
9.
BetriuAMartinez-AlonsoMArcidiaconoMV, et al. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. Nephrol Dialy Transplant2014; 29: 1415–1422.
10.
GaiZWangTVisentinM, et al. Lipid accumulation and chronic kidney disease. Nutrients2019; 11(4): 722. DOI: 10.3390/nu11040722
11.
AllonM. Vascular access for hemodialysis patients: new data should guide decision making. Clin J Am Soc Nephrol2019; 14: 954–961.
12.
LokCEHuberTSLeeT, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis2020; 75: S1–S164.
13.
XueHIxJHWangW, et al. Hemodialysis access usage patterns in the incident dialysis year and associated catheter-related complications. Am J Kidney Dis2012; 61: 123–130.
14.
SchmidliJWidmerMKBasileC, et al. Editor’s Choice - Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg2018; 55: 757–818.
15.
SkandariMRShechterSMZalunardoN. Optimal vascular access choice for patients on hemodialysis. Manuf Serv Oper Manage2015; 17: 608–619.
16.
CuiJKessingerCWJhajjHS, et al. Atorvastatin reduces in vivo fibrin deposition and macrophage accumulation, and improves primary patency duration and maturation of murine arteriovenous fistula. J Am Soc Nephrol2020; 31: 931–945.
17.
CumpstonMLiTPageMJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of interventions. Cochrane Database Syst Rev2019; 10: ED000142.
18.
K/DOQI clinical practice guidelines on Chronic Kidney Disease Work Group and Evidence Review Team Membership. Am J Kidney Dis2002; 39: S11–S12.
19.
PieturaRJanczarekMZaluskaW, et al. Colour Doppler ultrasound assessment of well-functioning mature arteriovenous fistulas for haemodialysis access. Eur J Radiol2005; 55: 113–119.
20.
GilmoreJ. KDOQI clinical practice guidelines and clinical practice recommendations–2006 updates. Nephrol Nurs J2006; 33: 487488.
21.
HigginsJPThompsonSGDeeksJJ, et al. Measuring inconsistency in meta-analyses. BMJ2003; 327: 557–560.
22.
GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet2016; 388: 1659–1724. DOI: 10.1016/S0140-6736(16)31679-8. Erratum in: Lancet. 2017 Jan 7; 389(10064): e1.
23.
KotsevaKDe BackerGDe BacquerD, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol2019; 26: 824–835.
24.
GrundySMStoneNJBaileyAL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation2019; 139: e1046–e1081.
25.
MachFBaigentCCatapanoAL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J2020; 41: 111–188.
26.
JiBZhangSGongL, et al. The risk factors of mild decline in estimated glomerular filtration rate in a community-based population. Clin Biochem2013; 46: 750–754.
27.
LiuBCWuXCWangYL, et al. Investigation of the prevalence of CKD in 13,383 Chinese hospitalised adult patients. Clin Chim Acta2008; 387: 128–132.
28.
LeeDMJacksonKWKnowltonN, et al. Oxidative stress and inflammation in renal patients and healthy subjects. PLoS One2011; 6: e22360.
29.
WangFYePLuoL, et al. Association of risk factors for cardiovascular disease and glomerular filtration rate: a community-based study of 4925 adults in Beijing. Nephrol Dialy Transplant2010; 25: 3924–3931.
30.
Haiming HuangXXXiaoqinW. Correlation between serum thyroid hormone and lipid in patients with chronic kidney disease. J Clin Nephrol2015; 15(12): 714–719. (in Chinese).
31.
HommaKHommaYYamaguchiS, et al. Triglyceride-rich lipoproteins in chronic kidney disease patients undergoing maintenance haemodialysis treatment. Int J Clin Pract2012; 66: 394–398.
32.
HolzmannMJJungnerIWalldiusG, et al. Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. Ann Med2012; 44: 262–270.
33.
LinP. The risk factors of cardiovascular disease in patients with chronic kidney disease and its current research of treatment and control. Shanghai: Fudan University, 2013.
34.
ZhengWQianGHaoW, et al. Cardiovascular metabolic risk factors and glomerular filtration rate: a rural Chinese population study. Lipids Health Dis2016; 15: 180.
35.
WentaoH SLPeijiaLDesmondYHY, et al. Correlation between blood lipid levels and prognosis of cardiovascular events and all-cause death in patients with different stages of chronic kidney diseases. J New Med2020; 51(06): 439–444.
36.
HouXWangCZhangX, et al. Triglyceride levels are closely associated with mild declines in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels. PLoS One2014; 9: e106778.
37.
SunY. Study on the relationship between dyslipidemia and renal function and its influencing factors in patients with chronic kidney disease. Changchun: Jilin University. 2020; p.8.
38.
RenCXiaoliYBihongH, et al. Risk factors for arteriovenous fistula complications in hemodialysis patients. Chin J Blood Purification2017; 16(09): 631–634.
39.
AkinDOzmenSKayaR. A novel factor for primary arteriovenous fistula failure: hyperinsulinism. Ren Fail2016; 38: 1206–1209.
40.
GagliardiGMRossiSCondinoF, et al. Malnutrition, infection and arteriovenous fistula failure: is there a link?J Vasc Access2011; 12: 57–62.
41.
Jiaxiang DingDZWemdiDDanyingJ, et al. Analysis of risk factors for autogenous arterio-venous fistulas thrombosis in chronic hemodialysis patients. J Capital Med Univ2010; 31(01): 113–116.
42.
BojakowskiKDzabicMKurzejamskaE, et al. A high red blood cell distribution width predicts failure of arteriovenous fistula. PLoS One2012; 7: e36482.
43.
BilgicMAYilmazHBozkurtA, et al. Relationship of late arteriovenous fistula stenosis with soluble E-selectin and soluble EPCR in chronic hemodialysis patients with arteriovenous fistula. Clin Exp Nephrol2015; 19: 133–139.
44.
StolićRJovanovićATrajkovićG, et al. [Problem of creation of arteriovenous fistulae for hemodialysis in older patients]. Med Pregl2010; 63: 313–317.
45.
Xiaomei PengYLChaoqingWZengC, et al. Risk factors of dysfuction in autogenous internal arteriovenous fistula of patients with maintenance hemodialysis. Chin General Practice2017; 20(01): 67–70.
46.
LiYCuiWWangJ, et al. Factors associated with dysfunction of autogenous arteriovenous fistula in patients with maintenance hemodialysis: a retrospective study. Ann Palliat Med2021; 10: 4047–4054.
47.
YuexiuOSQChangpingLZhuanzhenW. Logistic regression analysis of risk factors for dysfunction of autologous arteriovenous fistula in hemodialysis patients. Anhui Med Pharmaceut J2019; 23(01): 72–75.
48.
Yongping ChenYLXinglanLMeilanQ, et al. Establishment of model predicting early patency rate of forearm arteriovenous fistula. J Clin Nephrol2018; 18(09): 559–563.
49.
Zezheng LiWWYanJIANGShiL, et al. Analysis of the factors relating to the dysfunction in autogenous arteriovenous fistula in maintenance hemodialysis patients. Chin J Integrated Traditional Western Nephrol2014; 15(11): 961–964.
50.
ZhaojunY. Analysis of influencing factors of internal fistula dysfunction in uremic patients. Clin Res Practice2021; 6(16): 53–54+73. DOI: 10.19347/j.cnki.2096-1413.202116014. (in Chinese).
51.
ViecelliAKLokCE. Hemodialysis vascular access in the elderly-getting it right. Kidney Int2019; 95: 38–49.
52.
GisteråAHanssonGK. The immunology of atherosclerosis. Nat Rev Nephrol2017; 13: 368–380.
53.
ShigenagaMKGimenoCJAmesBN. Urinary 8-hydroxy-2’-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc Natl Acad Sci USA1989; 86: 9697–9701.
54.
SimicMG. Urinary biomarkers and the rate of DNA damage in carcinogenesis and anticarcinogenesis. Mutat Res1992; 267: 277–290.
55.
MarchioPGuerra-OjedaSVilaJM, et al. Targeting early atherosclerosis: a focus on oxidative stress and inflammation. Oxid Med Cell Longev2019; 2019: 8563845.
56.
de BoerIHAstorBCKramerH, et al. Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol2008; 3: 125–132.
57.
BasharKConlonPJKheirelseidEA, et al. Arteriovenous fistula in dialysis patients: factors implicated in early and late AVF maturation failure. Surg J R Coll Surg Edinb Irel2016; 14: 294–300.
58.
HiltunenMOLaitinenMTurunenMP, et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation2000; 102: 2262–2268.
59.
WuMYLiCJHouMF, et al. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci2017; 18: 2034.
60.
GeovaniniGLibbyP. Atherosclerosis and inflammation: overview and updates. Clin Sci2018; 132: 1243–1252.
61.
PirilloANorataGDCatapanoAL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm2013; 2013: 152786.
62.
RapaSFDi IorioBRCampigliaP, et al. Inflammation and oxidative stress in chronic kidney disease-potential therapeutic role of minerals, vitamins and plant-derived metabolites. Int J Mol Sci2019; 21(1): 263. DOI: 10.3390/ijms21010263
63.
PoznyakAVNikiforovNGMarkinAM, et al. Overview of OxLDL and its impact on cardiovascular health: focus on atherosclerosis. Front Pharmacol2020; 11: 613780.
Jourde-ChicheNFakhouriFDouL, et al. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol2019; 15: 87–108.
66.
KattoorAJPothineniNVKPalagiriD, et al. Oxidative stress in atherosclerosis. Curr Atheroscler Rep2017; 19: 42.
67.
SarnakMJAmannKBangaloreS, et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol2019; 74: 1823–1838.
68.
BreyerMDSusztakK. The next generation of therapeutics for chronic kidney disease. Nat Rev Drug Discov2016; 15: 568–588.
69.
WolfDLeyK. Immunity and inflammation in atherosclerosis. Circ Res2019; 124: 315–327.
70.
BaeJCHanJMKwonS, et al. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort. Atherosclerosis2016; 251: 170–176.
71.
KassimatisTIGoldsmithDJ. Statins in chronic kidney disease and kidney transplantation. Pharmacol Res2014; 88: 62–73.
72.
HagerMRNarlaADTannockLR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord2017; 18: 29–40.
73.
KaysenGA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr2009; 19: 73–77.
74.
MassyZAde ZeeuwD. LDL cholesterol in CKD–to treat or not to treat?Kidney Int2013; 84: 451–456.
75.
PalmerSCCraigJCNavaneethanSD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med2012; 157: 263–275.
76.
SanguankeoAUpalaSCheungpasitpornW, et al. Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis. PLoS One2015; 10: e0132970.
77.
LawsonJHGlickmanMHIlzeckiM, et al. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet2016; 387: 2026–2034.
